

Type of Policy: <i>PROTECTION OF HUMAN RESEARCH PARTICIPANTS</i>	Category: Orlando Health Institutional Review Board (IRB)
---	--

Title: <i>New/Initial Protocol Submission/Full Board Review</i>	Policy #: 0330-1014
Page 1 of 2	Replaced #: ORMC Policy # 6000-305 MDACCO Policy # 1000-0001H
Issue Date: 7/19/95	Issued By: Orlando Health Institutional Review Board (IRB)
Revision Dates: 1/1/01, 3/20/02, 11/12/07, 10/29/12, 8/11/14, 8/16/17, 4/21/20, 11/15/22	Approved By: Philip Giordano, MD Institutional Official
	SIGNATURE ON FILE

I. PURPOSE:

This policy outlines the process for review, by the Orlando Health IRBs, of Human Subjects Research that is more than minimal risk.

II. DEFINITION: IRBNet is the electronic system used by Orlando Health IRBs for submission, review, and document storage of all research reviewed by Orlando Health IRBs. It can be accessed at www.IRBNet.org. IRB staff can provide training materials and in-person training for using the IRBNet web site.

III. POLICY:

Full Board Review: Human Subjects Research submissions that do not meet the criteria for Expedited Review or Exempt Review must be reviewed by the convened IRB (Full Committee Review).

IV. PROCEDURE:

The necessary forms required for IRB review of new protocol submissions are provided on the IRBNet website. Such documents and forms shall be submitted by the Principal Investigator and/or their research team to the IRB, via IRBNet submission, by the deadline for new/initial submissions. All new submissions must have electronic signature provided by the Principal Investigator and, if applicable, Co-Investigators via IRBNet tools.

A. New Protocol submission:

1. All submissions for approval must be accompanied by, but not limited to, an Orlando Health - IRB Application (online document in IRBNet), Informed Consent form (or waiver of informed consent form), Investigator's Brochure (as appropriate), Protocol, and a copy of the signed Form FDA 1572 (when appropriate). Refer to OH How to Submit to the IRB (found in IRBNet)
2. For any funded projects that include PHS and not PHS sponsored projects, a completed Financial Disclosure form is required for all investigators. When a COI is found please refer to policy #5706-0174.
3. Researchers submitting protocols for the first time should ensure their current curriculum vitae/resume and the appropriate CITI Completion Reports (showing modules completed) are uploaded into their own IRBNet User Profiles in order for these documents to be kept on record in IRBNet. This requirement applies to all members of the study team.
4. Completed submissions for new protocols to be reviewed by the Full Board must be submitted to the Institutional Review Board via IRBNet by the posted deadline. Any studies that are greater than minimal risk are reviewed by the Pre-Review committee, unless otherwise specified by the IRB. The Chair and/or Pre-Review committee members will determine if a study will move forward to a Full Board Review.

Type of Policy:	PROTECTION OF HUMAN RESEARCH PARTICIPANTS	Category:	Orlando Health Institutional Review Board (IRB)
-----------------	--	-----------	--

Title:	<i>New/Initial Protocol Submission/Full Board Review</i>	Policy #:	0330-1014
Page 2 of 2		Replaced #:	ORMC Policy # 6000-305 MDACCO Policy # 1000-0001H
Issue Date:	7/19/95	Issued By:	Orlando Health Institutional Review Board (IRB)
Revision Dates:	1/1/01, 3/20/02, 11/12/07, 10/29/12, 8/11/14, 8/16/17, 4/21/20,11/15/22	Approved By:	Philip Giordano, MD Institutional Official
SIGNATURE ON FILE			

- B. The Principal Investigator shall be in attendance at the Full Board meeting to present the information and answer any questions that may arise during discussion. If the Principal Investigator is unable to attend, he/she may appoint another member of the study personnel who is knowledgeable to present the facts. If no representative is in attendance at the meeting, the protocol will be tabled until the next meeting, unless otherwise specified by the IRB.
- C. The IRB shall review and have authority to approve, require modification(s) to, place restrictions on, or disapprove all research activities covered by this policy.
- D. No research activities may begin until all completed forms have been reviewed and approved by the IRB. The IRB shall notify investigators and the institution of its decisions via IRBNet. If the IRB disapproves a research proposal, a statement of the reasons for its decision shall be included in its notification. The Principal Investigator will have an opportunity to respond to the Board in person or via IRBNet correspondence. **Reversal of IRB disapproval is only authorized by a majority vote upon the investigator's response to the issues of disapproval. Any additional information must be posted on IRBNet in the appropriate submission package for the protocol.**
- E. The IRB has the authority to observe, or have a third party observe, the consent process and the research at any time, with or without prior notification to the investigator.

V. REFERENCES

- A. Expedited Review Policy # 0330-1003
- B. Exempt Review Policy # 0330-1004
- C. IRB Authority and Jurisdiction Policy # 0330-1005
- D. Financial Conflicts of Interest for Grants and Research Policy # 5706-0174
- E. OH IRB How to Submit to the IRB (IRBNet)

VI. ATTACHMENTS

None.